In obesity, Lilly removed a dual amylin calcitonin receptor agonist (DACRA) from its phase 1 pipeline. Lilly got into DACRAs by partnering with KeyBioscience in 2017. At one time, the Big Pharma was ...

ATH434 has been shown preclinically to reduce α-synuclein pathology and preserve neuronal function by restoring normal iron balance in the brain. As an iron chaperone, it has excellent potential to ...

Alterity Therapeutics (ASX: ATH) has announced positive topline results from a Phase 2 clinical trial of lead candidate ...

LATE-NC diagnostic criteria improve differentiation from Alzheimer's, addressing challenges in memory-loss syndromes and guiding therapeutic interventions.

MNDs are neurological disorders that destroy motor neurons, the cells that control skeletal muscle activity such as walking, breathing, speaking, and swallowing.

HighlightsTopline data for ATH434-201 randomized, double-blind Phase 2 clinical trial on track for expected release by early February ...

Pathological liars are rare to find, but not that rare. There’s still a decent chance you might know one, and if you notice certain signs, you can figure out they're a pathological liar before ...

Emil Kraepelin formulated the initial nosology of Alzheimer's disease in the first decade of the 20th century. Nowadays, clinical and pathological presentations (including those associated with ...

Villous atrophy occurs when your intestinal villi—the microscopic, finger-like tentacles that line the wall of your small intestine—erode away, leaving a virtually flat surface. Celiac disease, an ...

dGraduate Institute of Biomedical Engineering, College of Medical Science and Technology, Taipei Medical University, Taipei, Taiwan eGraduate Institute of Molecular Medicine, and Graduate Institute of ...

But until recently, we haven’t had any therapeutics to target the root cause of geographic atrophy, an advanced form of dry AMD. Pegcetacoplan (Syfovre) is the first FDA-approved drug to slow ...